These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32779487)

  • 1. Drugging all RAS isoforms with one pocket.
    Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
    Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugging an undruggable pocket on KRAS.
    Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
    Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
    Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
    Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
    Quinlan MP; Quatela SE; Philips MR; Settleman J
    Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress on Covalent Inhibition of KRAS(G12C).
    Westover KD; Jänne PA; Gray NS
    Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
    Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
    J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
    Tang D; Kroemer G; Kang R
    Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
    Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
    Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Nonfunctional Ras.
    Nussinov R; Jang H; Gursoy A; Keskin O; Gaponenko V
    Cell Chem Biol; 2021 Feb; 28(2):121-133. PubMed ID: 33440168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reactivity-driven biochemical mechanism of covalent KRAS
    Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
    Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
    Goody RS; Müller MP; Rauh D
    Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing RAS Function with Monobodies.
    Khan I; O'Bryan JP
    Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.